Vedanta Biosciences “significantly” reduced its headcount to maintain progress and focus resources on a Phase III study of oral drug candidate VE303 for recurrent Clostridioides difficile infection (rCDI).
Vedanta Biosciences “significantly” reduced its headcount to maintain progress and focus resources on a Phase III study of oral drug candidate VE303 for recurrent Clostridioides difficile infection (rCDI).